BOSTON, April 2, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries..

波士顿，2024年4月2日/PRNewswire/--今天，正在构建细胞编程和生物安全领先平台的银杏生物工程（NYSE:DNA）宣布收购Modular Therapeutics的细胞治疗平台资产，包括其嵌合抗原受体（CAR）和开关受体库。

Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases. In contrast to legacy cell therapy design, the company uses a combinatorial approach to build and screen cell therapy components that work in concert with one another to yield novel cell behaviors..

Modular Therapeutics是一家细胞工程公司，专注于设计针对自身免疫性疾病的下一代细胞疗法。与传统的细胞疗法设计相反，该公司使用组合方法来构建和筛选细胞疗法组件，这些组件彼此协同工作以产生新的细胞行为。

Modulus has used its platform to develop and screen libraries of novel NK-specific and T-cell specific CAR and switch receptor designs, which enable improved control and performance of immune cell-based therapies. This technology has the potential to improve the safety and efficacy of cell therapies by allowing for more precise control over activation and targeting.

Module利用其平台开发和筛选新型NK特异性和T细胞特异性CAR和开关受体设计的文库，从而改进了基于免疫细胞的疗法的控制和性能。这项技术有可能通过更精确地控制激活和靶向来提高细胞疗法的安全性和有效性。

Modulus' CAR-NK and CAR-T components are designed to enhance proliferation and cytotoxicity, even in inhospitable cellular environments, providing a deeper and more durable response against target cells..

模量的CAR-NK和CAR-T成分旨在增强增殖和细胞毒性，即使在恶劣的细胞环境中，也能对靶细胞产生更深入和更持久的反应。

Modulus' assets complement Ginkgo's extensive cell therapy capabilities. With this addition, Ginkgo looks forward to supporting its customers who are improving the performance of T-cell and NK-cell based CAR therapies to treat solid tumors, autoimmune, and other diseases.

模量的资产补充了银杏广泛的细胞治疗能力。除此之外，银杏期待着支持其客户，他们正在改善基于T细胞和NK细胞的CAR疗法的性能，以治疗实体瘤，自身免疫和其他疾病。

Jason Kelly, CEO and co-founder of Ginkgo Bioworks: 'Modulus Therapeutics has built an array of incredible cell therapy assets that we are excited to add into the significant cell therapy capabilities Ginkgo has developed to date. Modulus' CAR and switch receptor designs and libraries seamlessly integrate into our existing infrastructure and offerings.

Ginkgo Bioworks首席执行官兼联合创始人杰森·凯利（JasonKelly）：“模疗法（Modular Therapeutics）已经建立了一系列令人难以置信的细胞疗法资产，我们很高兴能够将这些资产添加到银杏迄今为止开发的重要细胞疗法功能中。Modular的汽车和交换机接收器设计和库无缝集成到我们现有的基础设施和产品中。

We are excited to put these new assets to work for our customers and contribute to the transformative advancements in CAR and cell therapies.'.

我们很高兴将这些新资产用于我们的客户，并为CAR和细胞疗法的变革性进步做出贡献。”

Max Darnell, CEO and co-founder of Modulus Therapeutics: 'At Modulus, we have always been motivated by enhancing access to cutting-edge cell therapy innovation. We're very pleased that Ginkgo Bioworks shares this commitment and can leverage our technology to help transform oncology and autoimmune cell therapies.

Modular Therapeutics首席执行官兼联合创始人马克斯·达内尔（Max Darnell）：“在Modular，我们一直致力于增强对尖端细胞疗法创新的获取。我们很高兴银杏生物工程公司也有这样的承诺，可以利用我们的技术来帮助转变肿瘤学和自身免疫细胞疗法。

We are thrilled to contribute our innovative designs to the Ginkgo ecosystem, and look forward to seeing these tools deployed across a range of Ginkgo-partnered programs.'.

我们很高兴能为银杏生态系统贡献我们的创新设计，并期待着看到这些工具在一系列银杏合作项目中部署。”

Ginkgo's platform works to enable its partners to sample CAR domains with a variety of functional roles and structural positions, sourced from diverse immune cell types. This approach to cell therapy discovery allows partners to thoroughly sample the breadth of therapeutic activities a CAR can produce.

银杏的平台使其合作伙伴能够对来自不同免疫细胞类型的具有各种功能角色和结构位置的CAR域进行采样。这种细胞疗法发现的方法允许合作伙伴彻底采样汽车可以产生的治疗活动的广度。

Last year, Ginkgo entered a partnership with the Wisconsin Alumni Research Foundation (WARF) to discover and develop next-generation CAR-T cell therapies. Ginkgo also presented new data on its high throughput pooled screening method to discover novel CAR-T designs for solid tumors at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in 2022, as well as data on its high-throughput screening platform for chimeric antigen receptor (CAR) libraries at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in 2023.

去年，银杏与威斯康星校友研究基金会（WARF）建立了合作关系，以发现和开发下一代CAR-T细胞疗法。在2022年举行的第37届癌症免疫治疗学会（SITC）年会上，银杏还提供了有关其高通量汇总筛选方法的新数据，以发现针对实体瘤的新型CAR-T设计，以及2023年第26届美国基因与细胞治疗学会（ASGCT）年会上其高通量筛选嵌合抗原受体（CAR）文库平台的数据。

The poster highlighted Ginkgo's Foundry-enabled methods for large-scale, combinatorial library design and screening of CAR domains for improved persistence. Ginkgo expects Modulus' cell therapy assets to help Ginkgo continue to strengthen its CAR-T research & development offerings..

海报强调了银杏的铸造启用方法，用于大规模组合文库设计和筛选CAR域以提高持久性。银杏希望模量的细胞治疗资产能够帮助银杏继续加强其CAR-T研发产品。

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats.

银杏生物工程（Ginkgo Bioworks）是细胞编程的领先水平平台，提供灵活的端到端服务，为食品和农业、制药、工业和特种化学品等不同市场的组织解决挑战。银杏生物安全与公共卫生部门（Ginkgo’s biosecurity and public health unit）由银杏（Ginkgo）牵头，正在建设全球生物安全基础设施，以增强政府、社区和公共卫生领导人预防、检测和应对各种生物威胁的能力。

For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn..

有关更多信息，请访问ginkgobioworks.com和concentricbygingo.com，阅读我们的博客，或通过社交媒体渠道关注我们，如X（@gingo和@ConcentricByGBW）、Instagram（@ginkgobioworks）、Threads（@ginkgobioworks）或LinkedIn。

Modulus is engineering next-generation immune cell therapies. By leveraging modern molecular engineering tools, deployed in a cell therapy-specific context, Modulus is rewiring immune cells to achieve unique sense-and-respond capabilities without the need for synthetic gene circuits. Modulus is focused on novel context-responsive CAR-NK cells in autoimmunity that feed themselves off of the autoimmune microenvironment for enhanced safety and efficacy.

模量正在设计下一代免疫细胞疗法。通过利用现代分子工程工具，部署在特定于细胞治疗的环境中，Modular正在重新连接免疫细胞，以实现独特的感知和响应能力，而无需合成基因电路。模量专注于自身免疫中的新型背景反应性CAR-NK细胞，这些细胞以自身免疫微环境为食，以增强安全性和有效性。